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Summary. Postpartum hemorrhage is the leading cause of maternal mortality and severe morbidity. 
Despite efforts to improve maternal outcomes, management of postpartum hemorrhage still faces 
at least four challenges, discussed in this review. First, current definitions for severe postpartum 
hemorrhage hamper early identification of women with high risk of adverse outcome. Adaptations 
to the definitions and the use of clinical tools such as shock index and early warning systems may 
facilitate this early identification. Second, surgical and radiological interventions to prevent 
hysterectomy are not always successful. More knowledge on the influence of patient and bleeding 
characteristics on the success rates of these interventions is necessary. Scarce data suggest that 
early timing of intra-uterine balloon tamponade may improve maternal outcomes, whereas early 
timing of arterial embolization seems to be unrelated to maternal outcomes. Third, fluid 
resuscitation with crystalloids and colloids is unavoidable in the early phases of postpartum 
hemorrhage, but may result in dilutional coagulopathy. Effects of different volumes of clear fluids on 
the occurrence of dilutional coagulopathy and maternal outcomes is unknown. Fourth, a better 
understanding of diagnosis and correction of coagulopathy during postpartum hemorrhage is 
needed. Low plasma fibrinogen levels at the start of postpartum hemorrhage predict progression to 
severe hemorrhage, but standard coagulation screens are time-consuming. A solution may be point-
of-care coagulation testing, however, clinical usefulness during postpartum hemorrhage has not 
been demonstrated. To date, early administration of tranexamic acid is the only hemostatic 
intervention that was proven to improve outcomes in women with postpartum hemorrhage. 
 
Keywords: blood transfusion, hemostasis, point-of-care testing, postpartum hemorrhage, 
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Introduction 
In 2014, the WHO concluded from a systematic analysis that postpartum hemorrhage accounts for 
almost one fifth of maternal deaths worldwide, ranging from 8% of all maternal deaths in developed 
regions to 29% in Eastern Asia and 32% in Northern Africa [1]. Incidences of postpartum hemorrhage 
continue to increase, even in high-resource settings [2-7]. Depending on the definition used, the 
incidence of postpartum hemorrhage ranges from 3 to 8% of all deliveries [2-4, 6].   
Main causes of postpartum hemorrhage are uterine atony and placental problems including 
retained placenta and abnormally invasive placenta. Even though numerous risk factors for 
postpartum hemorrhage have been identified, it is still an unpredictable obstetric emergency. As a 
consequence, every woman is considered at risk of developing postpartum hemorrhage following 
delivery[8]. 
Quality improvement tools such as triggers, bundles, checklists and protocols in women with 
postpartum hemorrhage may improve maternal mortality and severe maternal morbidity [9-11]. 
Introduction of these tools was reported to reduce the use of blood products and improve patient 
safety in women with postpartum hemorrhage [11]. However, there may be room for improvement 
in the separate components of these tools. Consequently, optimization of the management of 
ongoing postpartum hemorrhage still faces numerous challenges  
In this article, we review the literature on these controversial issues. We discuss 1) adaptations to 
postpartum hemorrhage definitions and clinical tools for early identification of women at high risk of 
adverse outcome, 2) timing of obstetric interventions to stop bleeding, 3) timing of switch from 
volume resuscitation with clear fluids to transfusion of packed red blood cells and 4) timing of 
hemostatic interventions to correct coagulopathy in women with severe postpartum hemorrhage.  
 
Improving maternal outcomes: timely recognition of patients with severe postpartum hemorrhage  
Definition of severe postpartum hemorrhage 
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Currently, postpartum hemorrhage and its severity are defined by estimated blood loss within 24 
hours following delivery [12]. Cut-off values of 500 and 1000 mL are used for defining postpartum 
hemorrhage, with the latter mostly used in high-resource settings [13]. However, these cut-off 
values are relatively poor in identifying women with high risk of severe maternal morbidity and 
mortality, as only a small proportion of women that reach these cut-off values of blood loss progress 
to hemorrhage leading to hysterectomy or maternal death.  
In a recent Delphi study performed by the International Network of Obstetric Surveillance 
Systems (INOSS), consensus definitions of several conditions of severe maternal morbidities were 
developed.  The proposed definition for severe primary postpartum hemorrhage was blood loss 
exceeding 2000 mL and/or the need of transfusion of at least four units of packed red blood cells 
[14]. This definition enables selection of women with a higher risk of adverse maternal outcome 
than women with blood loss exceeding 500 or 1000 mL, while facilitating international comparisons 
of incidences of severe maternal morbidity and mortality as a result of postpartum hemorrhage. In 
practice, however, this definition excludes the possibility of early identification of women at high risk 
of adverse maternal outcome, as this definition reflects an intermediary or even end stage of 
hemorrhage.     
Qualitative studies among experienced birth attendants show that severity of hemorrhage not 
only depends on volume of blood loss, but also on rate of bleeding and physiological response to 
bleeding [15]. In recognition of these determinants, several guidelines incorporated clinical signs of 
shock to express physiological response to bleeding in the definition of severe postpartum 
hemorrhage [16, 17]. In addition, an international expert panel proposed to add response to 
treatment as a determinant of severity to the definition of postpartum hemorrhage, and suggested 
defining severe postpartum hemorrhage as persistent (ongoing) hemorrhage >1000 mL within 24 
hours following birth that continues despite the use of initial measures to stop bleeding [8]. Adding 
refractoriness to initial measures to the definition of postpartum hemorrhage has the potential 
advantage of early identification of women at high risk of adverse maternal outcome by considering 
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women as having a severe hemorrhage as soon as initial uterotonic treatment fails to stop 
hemorrhage. Whether or not this adaptation will improve maternal outcomes might become clear in 
the near future, as this extension has already been implemented in a national guideline (figure 
1)[18].   
 
Clinical tools for early recognition of women with severe postpartum hemorrhage  
Cardiac output increases during pregnancy due to a physiologic increase in heart rate and blood 
volume and blood pressure decreases due to lower systemic vascular resistance [19, 20]. Cardiac 
output further increases during labor and delivery, because of a higher preload caused by uterine 
contractions. After delivery, preload further increases as a result of relief of inferior vena cava 
compression by the gravid uterus and the return of uterine blood to maternal circulation. As a result, 
early recognition of a deterioration in clinical condition in women with postpartum hemorrhage is 
difficult [21].  
This early detection of deterioration in clinical condition has gained a lot of interest over the past 
decades, both in the pregnant and non-pregnant patients. Recent studies examined whether the 
shock index and early warning systems can be used to monitor women with postpartum 
hemorrhage. The shock index is the ratio of heart rate to systolic blood pressure. In the non-
pregnant population a shock index >1.0, thus a higher heart rate than systolic blood pressure 
measured at least once in the observation period, has been associated with morbidity and mortality 
in critically ill patients suffering trauma, sepsis and after surgery [22-25]. A study among 8874 
women without postpartum hemorrhage reported a range of 0.5 to 1.1 for the shock index 
immediately following delivery [26]. Another study among 233 women with postpartum hemorrhage 
with blood loss exceeding 1500 mL concluded that a shock index ≥1.7 was a predictor of intensive 
care unit admission, invasive surgical procedures and transfusion of ≥4 units of packed red blood 
cells, with respective area under the curves 0.75 (95% confidence interval 0.63-0.87), 0.62 (0.45-
0.79) and 0.67 (0.58-0.76) [27]. Correspondingly, a secondary analysis of 958 women with 
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hypovolemic shock due to postpartum hemorrhage in low-resource settings showed similar results 
for a composite maternal outcome for this cut-off value of ≥1.7 for the shock index, area under the 
curve of 0.76 (0.71-0.81). The composite outcome in this study consisted of maternal death, severe 
end-organ failure, intensive care unit admission, emergency hysterectomy and transfusion of ≥5 
units of packed red blood cells [28].   
Early warning scoring systems were also introduced to improve early recognition of life 
threatening conditions. These scores are repeatedly calculated based on physiological parameters: 
heart rate, systolic blood pressure, respiratory rate, temperature and mental state [29]. The 
principle is that acute deterioration is preceded by subtle changes in these physiological parameters, 
and that these would be noticed earlier using early warning scoring systems than waiting for obvious 
changes in individual parameters [29, 30].  In a systematic review, early warning systems were 
shown to successfully predict mortality in non-pregnant patients in different clinical settings [31]. 
Another systematic review focused on critically ill patients and concluded that the use of many 
different early warning score systems with different trigger thresholds hampered meta-analysis of 
conflicting findings [30].  
Studies on the use of early warning systems in obstetric populations generally focus on several 
severe conditions in pregnancy and puerperium simultaneously, including preeclampsia, postpartum 
hemorrhage and sepsis. A retrospective study among 702 obstetric patients, in a low-resource 
setting, admitted to the intensive care unit showed an area under the curve for maternal death for 
high early warning scores of 0.84 (0.75-0.92) [32] . Similarly, several other obstetric early warning 
systems also showed to be able to differentiate well between women with and without an adverse 
outcome [33-36]. Maternal outcomes were also reported to improve after introduction of a 
Maternal Early Warning Trigger tool, as compared to before introduction of the tool. In this study, 
hysterectomy rates decreased from 0.94/1000 to 0.63/1000 deliveries [37].   
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To conclude, adding refractoriness to initial measures to definitions of severe postpartum 
hemorrhage may warrant early identification of women at high risk of adverse outcome. Clinical 
tools as shock index and early warning scores seem to have a good ability to predict adverse 
outcomes in women with postpartum hemorrhage. Further studies to quantify the added clinical 
value with respect to preventing adverse outcomes are to be awaited.  
 
Improving maternal outcomes: obstetric interventions to stop bleeding 
Initial measures to stop bleeding depend on the primary cause of hemorrhage. In case of uterine 
atony, the uterus is massaged as soon as uterine atony is diagnosed, and uterotonic agents are 
administered. The first-choice uterotonic agent is oxytocin, but if unavailable, misoprostol or ergot 
alkaloids are recommended [12, 38]. If postpartum hemorrhage occurs with the placenta still in 
utero, manual removal of the placenta is performed. If the placenta has already been delivered,  
examination of the uterine cavity under anesthesia to exclude placental remnants should be 
considered. However, when postpartum hemorrhage proves to be refractory to these initial 
measures to stop bleeding, guidelines prostaglandins as second-line uterotonic agents for treatment 
of uterine atony [16, 18, 39]. Bimanual uterine compression is recommended as a temporizing 
measure awaiting definitive uterotonic, surgical or radiological interventions to stop bleeding [12]. 
Surgical and radiological interventions to stop bleeding include intrauterine balloon tamponade, 
arterial embolization, arterial ligation and uterine compression sutures (brace sutures). If bleeding 
persists despite these interventions, hysterectomy should be performed.  
Hysterectomy to avoid maternal death should be performed “sooner rather than later”, 
according to the Royal College of Obstetricians & Gynaecologists (RCOG)[16]. Intrauterine balloon 
tamponade, arterial embolization, arterial ligation and uterine compression sutures have all been 
reported to be effective in stopping hemorrhage and preventing hysterectomy [40-51]. Yet, if 
unsuccessful, these interventions may also delay hysterectomy, especially because they are 
performed with low frequency, and thus, experience with these techniques may be insufficient.  
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When it comes to these interventions to avoid hysterectomy in women with severe postpartum 
hemorrhage two important issues on the appropriate timing of hysterectomy need to be resolved. 
First, we need to be able to recognize situations in which hysterectomy will be needed anyway. If 
surgical and radiological interventions fail most of the time in women with already high volumes of 
blood loss, high bleeding rates or who are hemodynamically unstable at moment of employment of 
these interventions, perhaps treating physicians should immediately perform the hysterectomy [52-
54].    
Second, we would argue for more insight into the interaction between the timing of the surgical 
and radiological and interventions and their success rates. Early employment of these interventions 
could minimize delay in hysterectomy in women in whom the bleeding proves refractory to these 
interventions. A study among 420 women with estimated blood loss >500 mL after vaginal delivery 
and >1000 mL after cesarean delivery assessed the effect of timing of uterine balloon tamponade 
and uterine artery embolization on maternal morbidity including hysterectomy and intensive care 
unit admission [55]. Timing of intervention was expressed as a function of estimated blood loss at 
the moment of employment of the intervention, and early timing of balloon tamponade (n=48) was 
associated with improved maternal outcomes. For early timing of arterial embolization (n=20), this 
association was not shown. Larger studies are needed to know whether these findings are robust, 
and whether earlier surgical and radiological interventions to stop bleeding result in a reduction in 
adverse maternal outcomes.  
In conclusion, a better understanding of the influence of patient and bleeding characteristics and 
timing of interventions on the success rates of surgical and radiological interventions to stop 
bleeding is necessary to improve outcomes of women with postpartum hemorrhage.   
 
Improving maternal outcomes: timing of switch from resuscitation with clear fluids to transfusion 
of blood products 
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Fluid resuscitation should start as soon as the severity of postpartum hemorrhage becomes evident, 
to maintain circulating blood volume and preserve tissue oxygenation [8]. The first stage of fluid 
resuscitation consists of administration of crystalloids and colloids, and in case of ongoing 
hemorrhage, this stage is followed by the second stage consisting of transfusion of blood products.  
In addition to abovementioned goals of resuscitation, blood products are also administered to 
support hemostasis and correct coagulopathy. Transfusion of plasma provides deficient coagulation 
factors, and packed red blood cells may also support primary hemostasis through different 
mechanisms. Red blood cells in the center of the vessel lumen may increase platelet concentrations 
near the endothelium [56]. Theoretically this so-called margination of platelets might support 
primary hemostasis, but this has not been supported by quantitative evidence. In addition, red blood 
cells may enhance platelet reactivity [57, 58], support shear-induced platelet aggregation [59] and 
support thrombin generation by exposing procoagulant phospholipids [60-62].  
Fluid resuscitation with high volumes of crystalloids and colloids, induces dilution of clotting 
factors and platelets, causing dilutional coagulopathy and thus aggravating hemorrhage [63]. In 
women with severe postpartum hemorrhage it has never been assessed, nonetheless, which 
volumes of clear fluids cause dilutional coagulopathy, nor whether dilutional coagulopathy 
contributes to adverse maternal outcome. A study examining varying degrees of hemodilution in 
healthy volunteers showed both in vitro and in vivo that hemodilution with normal saline decreased 
concentrations of coagulation and antifibrinolytic factors (α2-antiplasmin and thrombin-activatable 
fibrinolysis inhibitor (TAFI)), and decreased thrombin generation [64, 65]. Impaired thrombin 
generation was also confirmed in bleeding patients with dilutional coagulopathy during major 
surgery, concomitant with impaired fibrin clot formation [66]. In these patients, volume of 
crystalloids, colloids, but also red blood cells, exceeded 5L.  
Moreover, colloid fluids have been associated with impairment of different aspects of 
coagulation. Colloid fluids like hydroxyethyl starches, dextrans and gelatins have been associated 
with impaired platelet function, inhibition of fibrin polymerization and increase of fibrinolysis, and 
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may lead to decreased levels of von Willebrand factor [65, 67]. Clinically relevant effects of colloid 
fluids on coagulation in non-pregnant patients seem to arise when larger volumes are administered 
[67]. Effects of administration of colloid fluids on adverse maternal outcome in women with 
postpartum hemorrhage are unknown.  
The RCOG guideline on prevention and management of postpartum hemorrhage recommends  a 
maximum volume of clear fluids of 3.5L before start of blood transfusion, comprising up to 2L 
crystalloids and 1.5L colloids [16]. This advice was based on consensus from a Working Party of 
Haemostasis and Thrombosis Task Force [68].  However, thus far there is insufficient quantitative 
evidence to support this hypothesis. As a consequence, it is uncertain which volumes and 
combination of clear fluids increase the risk of adverse maternal outcome in women with 
postpartum hemorrhage.  
Summarizing, resuscitation with clear fluids in women with postpartum hemorrhage is generally 
unavoidable because of the unpredictability of postpartum hemorrhage. However, switching to 
transfusion of blood products when these are available would probably reinforce hemostasis and 
thus be beneficial for women with ongoing postpartum hemorrhage.   
 
Improving maternal outcomes: timing of hemostatic interventions to correct coagulopathy  
 Diagnosis of coagulopathy in women with postpartum hemorrhage 
Pregnancy is a hypercoagulable state due to changes in the coagulation system throughout the 
pregnancy (figure 2) [69-72]. The majority of procoagulant factors increase, while the level of protein 
S as endogenous anticoagulant and fibrinolytic activity decrease. The most marked increases in 
procoagulants seem to occur in concentrations of factor VII, factor VIII, von Willebrand factor and 
fibrinogen [72]. Fibrinogen concentration increases to approximately twice the non-pregnant values 
at term, with levels between 4 and 6 g/L [71]. The physiologic increase in plasma volume in 
pregnancy may also cause a mild thrombocytopenia [73]. Altogether, haemostatic changes of 
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pregnancy lead to a slightly shortened prothrombin time (PT) and activated partial thromboplastin 
time (APTT), within the range of non-pregnant reference values [69, 71, 73].   
A woman with ongoing postpartum hemorrhage may develop coagulopathy due to loss, dilution 
and consumption of platelets and clotting factors. All factors involved in coagulation may become 
deficient, procoagulant and anti-coagulant proteins, as well as fibrinolytic and antifibrinolytic 
proteins [66]. Impairment of hemostasis may also occur because of disseminated intravascular 
coagulation [64]. Risk factors for developing disseminated intravascular coagulation are placental 
abruption, preeclampsia with HELLP syndrome, and amniotic fluid embolism [64]. 
The monitoring of coagulation in women with severe postpartum hemorrhage is subject of 
debate. Conventional hemostasis assays such as the PT and APTT tests are considered unsuitable 
because of an inability to detect specific changes in coagulation, a disregard of large parts of 
coagulation (i.e. platelet function and fibrinolysis) and long turn-around times [74]. Studies that 
assessed the changes in PT and APTT during postpartum hemorrhage reported values within non-
pregnant reference values during postpartum hemorrhage, even with high volumes of blood loss 
[75, 76].  Among 356 women with postpartum hemorrhage PT and aPTT measured at 1-1.5L blood 
loss were not associated with progression to blood loss >2.5L [77].  
Data on changes in platelet counts and function during postpartum hemorrhage are scarce. 
Available studies report minimal decreases of platelet counts during postpartum hemorrhage, and 
platelet counts measured in women with blood loss between 1 and 1.5L seem not to be associated 
with progression to higher volumes of blood loss [78, 79].    
Several observational studies reported a plasma fibrinogen level measured early during 
postpartum hemorrhage to be predictive of progression to more severe bleeding and invasive 
procedures in women with postpartum hemorrhage [75, 77, 79-81]. Positive predictive value of a 
fibrinogen level ≤2g/L for progression to severe bleeding was reported to be 100%, whilst negative 
predictive value of fibrinogen >4 g/L was 79% [79]. Reported odds ratios for fibrinogen <2 g/L for 
progression to severe hemorrhage were 12.0 (95% confidence interval 2.6-56.1) and for fibrinogen 
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between 2 and 3 g/L 1.9 (1.2-3.1) [80]. A point-of-care test to measure fibrinogen within a few 
minutes or seconds might be a promising monitoring tool for women with severe postpartum 
hemorrhage.    
Since obtaining results of standard coagulation screens are time-consuming, coagulation 
monitoring with point-of-care tests is increasingly used in women with severe postpartum 
hemorrhage to detect coagulopathy and guide hemostatic interventions. However, the clinical 
usefulness of thromboelastography and thromboelastometry in women with postpartum 
hemorrhage has not been established [74]. As with the standard coagulation screens, 
thromboelastography and thromboelastometry values are different from the non-pregnant 
population due to the prohemostatic changes of pregnancy [63, 74]. Several observational studies 
reported reference values for these point-of-care tests in pregnancy and the peripartum period, 
confirming the increased coagulability with faster initiation of coagulation and decreased fibrinolysis 
[82-84]. The next steps to be undertaken to eventually determine the clinical usefulness of these 
point-of-care tests in women with postpartum hemorrhage are 1) investigation of the changes in the 
measured values during postpartum hemorrhage and whether these measured values reflect 
impaired coagulation, as compared with standard coagulation assays, 2) investigation of  
appropriate interventions to correct these changes and 3) investigation of effects of the use of these 
tests in treatment algorithms for postpartum hemorrhage on clinically relevant maternal outcomes 
[85].   
Overall, there seem to be minimal changes in PT, aPTT and platelet counts during postpartum 
hemorrhage, and only low plasma fibrinogen concentrations seem associated with progression to 
larger bleeds. Clinical usefulness of thromboelastography and thromboelastometry in women with 
postpartum hemorrhage is yet to be determined.  
 
Correction of coagulopathy: early timing of fresh frozen plasma 
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Early timing of fresh frozen plasma, expressed as a high fresh frozen plasma to packed red blood 
cells ratio, seemed to reduce mortality in (non-pregnant) trauma patients in observational studies. 
Despite concerns about high risk of bias in these studies, massive transfusion protocols incorporating 
high ratio plasma and platelets to red blood cells were widely implemented in many different clinical 
settings with major hemorrhage. A randomized clinical trial among 680 trauma patients with major 
bleeding receiving either a plasma:platelets:red blood cells ratio of 1:1:1 or ratio 1:1:2 showed no 
statistically significant difference in 24 hours and 30 days mortality with risk differences -4.2% (95% 
confidence interval -9.6 to 1.1) and -3.7% (-10.2 to 2.7) [86]. Death from exsanguination, a secondary 
outcome, was significantly decreased in patients that received a high ratio as compared with a low 
ratio, difference -5.4% (-10.4 tot -0.5).  
In women with postpartum hemorrhage, studies on early timing of plasma to correct 
coagulopathy and improve maternal outcomes are limited. An observational before-and-after study 
among 142 women with severe postpartum hemorrhage, defined as postpartum hemorrhage 
requiring the second-line prostaglandin analogue sulprostone and packed red blood cells transfusion 
within six hours following delivery, compared fresh frozen plasma to red blood cells ratio of >0.5 
with ratio ≤0.5 on advanced interventional procedures [87]. To account for confounding by 
indication, propensity score matching was performed for the 41 women who received plasma. In this 
study, a low fresh frozen plasma to red blood cells ratio was associated with more advanced 
interventions, odds ratio 1.3 (1.1-1.5), suggesting a beneficial effect of administering plasma early 
during the course of postpartum hemorrhage [87].  
High ratios of plasma to red blood cells in women with postpartum hemorrhage were also 
studied within massive transfusion protocols. These massive transfusion packs were part of an 
obstetric hemorrhage protocol that included a whole series of other changes in management [11]. 
The combination of changes in management seemed to reduce blood product use in these women, 
but the ratios of blood products in the designated “obstetrics hemorrhage pack” were based on 
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evidence from trauma-related hemorrhage. Future studies need to address the comparison of 
different transfusion protocols for postpartum hemorrhage.  
Interestingly, in a recent observational study among 605 women with postpartum hemorrhage 
exceeding 1L of blood loss fresh frozen plasma was administered when thromboelastometry showed 
signs of fibrinogen deficiency (Fibtem A5 ≤15 mm)[88]. The women who did not reach Fibtem A5 
below 15 mm did not develop clinically significant hemostatic impairment, defined as continued 
bleeding and laboratory hemostatic failure (PT or aPTT >1.5 times the midpoint of the normal range 
or fibrinogen <2 g/L).  
Concluding, whether early administration of plasma during the course of postpartum hemorrhage 
improves maternal outcomes is still unclear.  
 
Correction of coagulopathy: early timing of tranexamic acid 
The effect of early administration of the antifibrinolytic agent tranexamic acid on maternal mortality 
and hysterectomy, as compared with placebo, has recently been assessed in the WOMAN trial, an 
international randomized controlled trial among 20060 women with postpartum hemorrhage [89].  
Postpartum hemorrhage was defined as 500 or 1000 mL depending on the mode of delivery, or 
blood loss causing hemodynamic instability. In this study all-cause mortality and composite outcome 
consisting of all-cause mortality and hysterectomy did not differ between women treated with 
tranexamic acid or placebo, corresponding risk ratios 1.02 (0.88-1.07) and 0.97 (0.87-1.09). 
Compared with placebo, death due to bleeding was significantly reduced in women treated with 
tranexamic acid, risk ratio 0.81 (0.65-1.00), and when administered within three hours following 
birth 0.69 (0.52-0.91). Importantly, administration of tranexamic acid was not associated with an 
increased risk of venous thromboembolism.  
Generalizability of the results of the WOMAN trial has been questioned, as almost all study 
participants (97%) were recruited in low-resource settings with high maternal mortality ratios [90-
92]. Effect of adding tranexamic acid to treatment algorithms in high-resource settings, with 
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advanced uterotonic, surgical and radiological interventions and transfusion of blood products 
available, on severe maternal morbidity and mortality remains unclear. A randomized controlled trial 
in a high-resource setting among 144 women with postpartum hemorrhage >800 mL following 
delivery compared the effect of high-dose tranexamic acid versus no tranexamic acid at moment of 
diagnosis of postpartum hemorrhage on total blood loss and invasive interventions to stop bleeding 
[93]. Tranexamic acid reduced median additional blood loss from moment of diagnosis of 
postpartum hemorrhage till end of bleeding slightly from 221 (interquartile range 105 to 564) to 173 
mL (59 to 377) (p-value 0.04), and there was no difference in advanced interventions to stop 
bleeding. Similarly, a before-and-after observational study in a high-resource setting including 289 
women with hemorrhage ≥500 mL following delivery, did not show a decrease in mean estimated 
blood loss after incorporating tranexamic acid in the treatment algorithm [94].  Additionally, early 
administration of tranexamic acid did not reduce adverse maternal outcome in a cohort study 
among 1260 women in the Netherlands with postpartum hemorrhage >1L and refractory to first-line 
obstetric interventions, odds ratio 0.9 (95% confidence interval 0.7-1.3) [95].  
In women with postpartum hemorrhage, early tranexamic acid seems to reduce the risk of 
maternal death due to exsanguination, with a favorable safety profile. However, the effect on 
maternal outcome in women with postpartum hemorrhage in high-resource settings may be limited. 
Future studies need to establish whether and when tranexamic acid improves clinical outcomes of 
women with postpartum hemorrhage. 
 
Correction of coagulopathy: early timing of fibrinogen concentrate 
Two randomized controlled trials investigated the effect of fibrinogen concentrate on maternal 
outcome. In the first trial, including 249 women with severe postpartum hemorrhage (after vaginal 
delivery >0.5L blood loss with retained placenta or >1L blood loss and intended manual exploration 
of the uterus, or >1L blood loss after caesarean delivery), pre-emptive treatment with 2g fibrinogen 
concentrate did not reduce the need for packed red blood cell transfusion or secondary outcomes, 
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as compared with placebo [96]. At inclusion mean blood loss was 1459 mL (standard deviation 476 
mL) and mean plasma fibrinogen level was 4.5 g/L (standard deviation 1.2). In the second trial, that 
randomized 55 women to fibrinogen concentrate or placebo, fibrinogen concentrate was 
administered in case the Fibtem A5-value, the thromboelastometry surrogate measure of plasma 
fibrinogen level, was below 15 mm [97]. This cut-off value for Fibtem was chosen after a preceding 
observational study among 365 women with postpartum hemorrhage (1-1.5L) indicating a predictive 
role of low Fibtem values for development of severe hemorrhage [77].  Median blood loss at time of 
study medication infusion was 1950 mL (interquartile range 1500-2285) and median fibrinogen level 
2.5 g/L. In this trial administration of fibrinogen concentrate did not reduce the number of 
transfused blood components.  
There are some published data on the use of algorithms to guide treatment of postpartum 
hemorrhage using thromboelastography and thromboelastometry. A before-and-after observational 
study with Rotem-guided fibrinogen concentrate administration reported a lower blood components 
use as compared with administration of fresh frozen plasma in major hemorrhage transfusion packs 
[98]. The study included  93 women with ongoing postpartum hemorrhage (>1500 ml) and 
coagulopathy defined as Fibtem A5 <12mm.  
Thus, administration of fibrinogen concentrate to women with ongoing postpartum hemorrhage 
and fibrinogen level above 2g/L does not seem associated with better maternal outcomes. Trials 
with fibrinogen administration in women with postpartum hemorrhage and plasma fibrinogen levels 
below 2g/L might demonstrate an effect on maternal outcomes. Before performing these trials, we 
need a test that provides fast and accurate estimates of a woman’s fibrinogen concentration.   
 
Correction of coagulopathy: recombinant activated factor VII  
Following an abundance of case series, only one randomized controlled trial has been published on 
administration of recombinant activated factor VII in women with postpartum hemorrhage for 
correction of coagulopathy [99]. In this open-label trial 84 women with severe postpartum 
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hemorrhage (>1.5L) refractory to the uterotonic agent sulprostone were randomized to a single dose 
of recombinant activated factor VII (60 ug/kg) or standard care. Randomization occurred one hour 
after onset of sulprostone, and outcomes were the need of advanced surgical or radiological 
intervention after randomization. Early administration of recombinant factor VII was associated with 
a reduction in advanced interventions to stop bleeding, relative risk 0.56 (0.42-0.76). However, 
information bias could have influenced the study results, as there was no allocation concealment in 
the study. Venous thromboembolism occurred in 5% of women who received recombinant activated 
factor VII, and did not occur in the women who underwent standard care. In a meta-analysis 
including only randomized controlled trials among non-obstetric bleeding patients this hemostatic 
agent was associated with arterial thromboembolism with odds ratio 1.7 (1.2-2.4), but not with 
venous thromboembolism (odds ratio 0.9 (0.7-1.2))  [100].   
 
Correction of coagulopathy: prothrombin complex concentrate 
To date, comparative studies on administration of prothrombin complex concentrate in women with 
postpartum hemorrhage have not been published. A randomized controlled trial comparing 
prothrombin complex concentrate and fibrinogen concentrate with fresh frozen plasma 
(NCT01910675) did not get permission from the appropriate Medical Ethical Committee, because it 
was not feasible to get proper informed consent from these acute, severely ill patients (personal 
communication).  
 
Conclusion 
In the optimization of management of postpartum hemorrhage we are still facing several challenges. 
Early recognition of women at high risk of adverse outcomes because of postpartum hemorrhage 
may be achieved by adaptations to the definition of severe postpartum hemorrhage and the use of 
clinical tools such as shock index and early warning scores.  
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Optimization of timing of surgical, radiological and hemostatic interventions in these women to 
stop bleeding and timing of switch from resuscitation with clear fluids to transfusion of blood 
products is of utmost importance to reach the goal of improving maternal outcomes. However, well-
designed studies on obstetric interventions to stop bleeding are scarce and results from studies on 
hemostatic interventions to stop hemorrhage in these women show conflicting results. Broadening 
our understanding of the interaction of individual patient characteristics with these interventions 
will enable us to improve management and outcomes of women with severe postpartum 
hemorrhage.   
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Figure 1. Algorithm from French guideline for management of postpartum hemorrhage after vaginal 
delivery, with definition of severe postpartum hemorrhage as postpartum hemorrhage refractory to 
initial measures to stop bleeding. PPH, postpartum hemorrhage; IV, intravenous; IM, intramuscular; 
IU, international unit; IAS, irregular antibody screening; CBC, complete blood count; PT, prothrombin 
time; ACT, activated clotting time; BLUA, bilateral ligation of uterine arteries; BLIIA, bilateral ligation 
of internal iliac arteries; rFVIIa, recombinant activated Factor VII. Adapted from Sentilhes et al. [18] 
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Figure 2. Hemostatic changes during normal pregnancy. The overall increase in pro-coagulant factors 
results in a hypercoagulable state which increases throughout pregnancy. Increases and decreases 
are relative to non-pregnancy. Positioning of factors is not indicative of the precise level of increase 
or decrease. FV, Factor V; FVII, Factor VII; FVIII, Factor VIII; FIX, Factor IX; FX, Factor X; FXI, Factor XI; 
FXII, Factor XII; FXIII, Factor XIII; PAI-1, plasminogen activator inhibitor 1; TAFI, thrombin activatible 
fibrinolysis inhibitor; TAT complex, thrombin-antithrombin complex; tPA, tissue plasminogen 
activator; vWF, von Willebrand factor. Solomon et al. [70] 
